# Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

> **NCT01238575** · PHASE4 · COMPLETED · sponsor: **Yale University** · enrollment: 62 (actual)

## Conditions studied

- Pervasive Development Disorders

## Interventions

- **OTHER:** placebo
- **DRUG:** extended-release guanfacine

## Key facts

- **NCT ID:** NCT01238575
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238575, "Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01238575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*